Smart CAR-T Nanosymbionts: archetypes and proto-models

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy
• Artificial Intelligence

Background:

• Personalized medicine, exemplified by chimeric antigen receptor T-cell (CAR-T) therapy, tailors cancer treatments to individual biological profiles.
• CAR-T therapy shows success in blood cancers but faces challenges in solid tumors, including manufacturing complexity, high costs, and toxicity.
• Nanotechnology and artificial intelligence (AI) offer potential solutions to enhance CAR-T therapy's efficacy and applicability.

Purpose of the Study:

• To introduce the 'Smart CART Nanosymbionts' framework, integrating AI and nanotechnology for advanced CAR-T therapies.
• To explore how this convergence addresses limitations in current CAR-T therapy, particularly for solid tumors.
• To discuss the ethical and regulatory considerations of this integrated therapeutic approach.

Main Methods:

• Leveraging AI for patient stratification, treatment response prediction, and CAR construct design.
• Utilizing nanotechnology for improved gene delivery, precise tumor targeting, and enhanced immune cell function.
• Developing methods for in vivo CAR-T production and real-time monitoring of CAR-T cell behavior and toxicity.

Main Results:

• The proposed framework enables optimization of lipid nanoparticle formulations for mRNA transfection.
• It facilitates specific targeting and modification of the tumor microenvironment.
• It supports improved in vivo CAR-T generation and aims to overcome barriers in solid tumor treatment.

Conclusions:

• The Smart CART Nanosymbionts framework represents a significant advancement in personalized cancer treatment.
• This integrated approach promises to increase the precision, accessibility, and effectiveness of CAR-T therapies.
• Addressing ethical and regulatory aspects is crucial for the successful clinical translation of these advanced therapies.